This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Satoh, K. Articles by Mizuno, S. Search for Related Content PubMed PubMed Citation Articles by Satoh, K. Articles by Mizuno, S.

Stroke, Vol 23, 1090-1092, Copyright © 1992 by American Heart Association

ARTICLES

Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke

K Satoh, H Yoshida, T Imaizumi, S Takamatsu and S Mizuno
Department of Pathologic Physiology, Hirosaki University School of Medicine, Japan.

BACKGROUND AND PURPOSE: Platelet-activating factor is a potent bioactive phospholipid and may play an important role in occlusive vascular diseases. To assess the inactivation of this autacoid in plasma, we measured platelet-activating factor acetylhydrolase activity in plasma low density and high density lipoproteins from patients with ischemic stroke. METHODS: Low density and high density lipoproteins were separated by ultracentrifugation from plasma of 33 patients with cerebral thrombosis and 31 age-matched healthy control subjects, and platelet-activating factor acetylhydrolase activity in each fraction was assayed. RESULTS: The average values of platelet-activating factor acetylhydrolase activity in low density lipoprotein from patients and control subjects were 41 +/- 18 and 29 +/- 17 nmol/ml per minute, respectively, and the difference was statistically significant (p less than 0.01 U test). There was no difference in activity in high density lipoprotein between the two groups (16 +/- 11 versus 14 +/- 9 nmol/ml per minute, respectively). CONCLUSIONS: The increased plasma platelet- activating factor acetylhydrolase activity in stroke patients is primarily attributable to the increased binding to low density lipoprotein, and this increase may be an adaptation to the augmented generation of platelet-activating factor in ischemic stroke.

This article has been cited by other articles:

				C. M. Ballantyne, R. C. Hoogeveen, H. Bang, J. Coresh, A. R. Folsom, L. E. Chambless, M. Myerson, K. K. Wu, A. R. Sharrett, and E. Boerwinkle Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study Arch Intern Med, November 28, 2005; 165(21): 2479 - 2484. [Abstract] [Full Text] [PDF]

				J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]

				H.-H. S. Oei, I. M. van der Meer, A. Hofman, P. J. Koudstaal, T. Stijnen, M. M.B. Breteler, and J. C.M. Witteman Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study Circulation, February 8, 2005; 111(5): 570 - 575. [Abstract] [Full Text] [PDF]

				S. Campo, M. A. Sardo, A. Bitto, A. Bonaiuto, G. Trimarchi, M. Bonaiuto, M. Castaldo, C. Saitta, S. Cristadoro, and A. Saitta Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals Clin. Chem., November 1, 2004; 50(11): 2077 - 2082. [Abstract] [Full Text] [PDF]

				D P Taggart, S M Browne, D T Wade, and P W Halligan Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist Heart, August 1, 2003; 89(8): 897 - 900. [Abstract] [Full Text] [PDF]

				S. Blankenberg, D. Stengel, H. J. Rupprecht, C. Bickel, J. Meyer, F. Cambien, L. Tiret, and E. Ninio Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis J. Lipid Res., July 1, 2003; 44(7): 1381 - 1386. [Abstract] [Full Text] [PDF]

				V. Tsimihodimos, S.-A. P. Karabina, A. P. Tambaki, E. Bairaktari, G. Miltiadous, J. A. Goudevenos, M. A. Cariolou, M. J. Chapman, A. D. Tselepis, and M. Elisaf Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia J. Lipid Res., February 1, 2002; 43(2): 256 - 263. [Abstract] [Full Text] [PDF]

				G.J. Hademenos, M.J. Alberts, I. Awad, M. Mayberg, T. Shephard, A. Jagoda, R.E. Latchaw, H.W. Todd, K. Viste, R. Starke, et al. Advances in the genetics of cerebrovascular disease and stroke Neurology, April 24, 2001; 56(8): 997 - 1008. [Abstract] [Full Text] [PDF]

				M. Hiramoto, H. Yoshida, T. Imaizumi, N. Yoshimizu, and K. Satoh A Mutation in Plasma Platelet-Activating Factor Acetylhydrolase (Val279->Phe) is a Genetic Risk Factor for Stroke Stroke, December 1, 1997; 28(12): 2417 - 2420. [Abstract] [Full Text]

				D. M. Stafforini, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott Platelet-activating Factor Acetylhydrolases J. Biol. Chem., July 18, 1997; 272(29): 17895 - 17898. [Full Text] [PDF]